Skip to main content
. 2019 Jul 12;98(28):e16328. doi: 10.1097/MD.0000000000016328

Figure 1.

Figure 1

Study attrition. 1L = first-line treatment, anti-PD1 = anti-PD1 monotherapies, BRAF or MEK = BRAF or MEK monotherapies, BRAF/MEK combo = BRAF/MEK combination therapy, ipi/nivo = ipilimumab/nivolumab combination therapy, ipi = ipilimumab, LOT = line of therapy, USON = US Oncology Network. Examples include: dabrafenib/ipilimumab/trametinib, carboplatin/paclitaxel, dabrafenib/ipilimumab and dabrafenib/nivolumab.